Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.36 |
| ▸ | HSPB1 | P04792 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GPR3 | P46089 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10015246 | 0.87 | MEN1 (0.48) | CYP2C19HPGDMEN1KMT2ACYP3A4 | |
| SCHEMBL1009702 | 0.84 | CYP1A2 (0.50) | CYP1A2CYP2C9CYP2C19HPGDMEN1 | |
| SCHEMBL8519279 | 0.82 | CYP2C19 (0.45) | CYP1A2CYP2C9CYP2C19HPGDMEN1 | |
| SCHEMBL13280266 | 0.80 | CYP3A4 (0.58) | CYP1A2CYP2C9CYP2C19HPGDMEN1 | |
| SCHEMBL561706 | 0.78 | MEN1 (0.64) | CYP1A2CYP2C9CYP2C19HPGDMEN1 | |
| SCHEMBL14055537 | 0.78 | HPGD (0.52) | CYP1A2CYP2C9CYP2C19HPGDMEN1 | |
| SCHEMBL1807898 | 0.77 | CYP3A4 (0.45) | CYP1A2CYP2C9CYP2C19HPGDMEN1 | |
| SCHEMBL17169180 | 0.76 | CES2 (0.53) | CYP1A2CYP2C9CYP2C19HPGDCYP3A4 | |
| SCHEMBL7028978 | 0.76 | LMNA (0.44) | MEN1KMT2ACYP3A4TSHRMAPT | |
| SCHEMBL790308 | 0.76 | CYP1A2 (0.40) | CYP1A2CYP2C9CYP2C19HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112442011-B | Prodrug compound and application thereof in treating cancers | 润佳（苏州）医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| EP-3904365-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2022-09-07 | — | — | EP | disclosed |
| EP-3904365-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2021-11-03 | — | — | EP | disclosed |
| CN-113493481-A | Entecavir monophosphate alaninamide phenol ester and medical application thereof | 北京君科华元医药科技有限公司 | 2021-10-12 | — | — | CN | disclosed |
| CN-112442011-A | Prodrug compound and application thereof in treating cancer | 润佳（苏州）医药科技有限公司 | 2021-03-05 | — | — | CN | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| US-RE47589-E1 | Phosphoramidate compounds and methods of use | NuCana plc (GB) | 2019-09-03 | — | — | US | disclosed |
| EP-3486251-A1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2019-05-22 | — | — | EP | disclosed |
| EP-3040340-B1 | CHEMICAL COMPOUNDS | NuCana plc (GB) | 2018-11-14 | — | — | EP | disclosed |
| US-9933655-B2 | Polarizer and display device comprising the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-04-03 | — | — | US | disclosed |
| EP-3040340-A1 | CHEMICAL COMPOUNDS | NuCana BioMed Limited (GB) | 2016-07-06 | — | — | EP | disclosed |
| EP-2955190-A2 | Chemical compounds | NuCana BioMed Limited (GB) | 2015-12-16 | — | — | EP | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-7951787-B2 | Phosphoramidate compounds and methods of use | CARDIFF PROTIDES LIMITED (GB) | 2011-05-31 | — | — | US | disclosed |
| US-20080105866-A1 | Method of fabricating organic thin film transistor using self assembled monolayer-forming compound containing dichlorophosphoryl group | SAMSUNG ELECTRONICS CO., LTD | 2008-05-08 | — | — | US | disclosed |
| US-20080105866-A1 | Method of fabricating organic thin film transistor using self assembled monolayer-forming compound containing dichlorophosphoryl group | SAMSUNG ELECTRONICS CO., LTD | 2008-05-08 | — | — | US | disclosed |
| US-20060142238-A1 | Chemical compounds | NuCana plc (GB) | 2006-06-29 | — | — | US | disclosed |
| EP-1646639-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | University College Cardiff Consultants, Ltd. (GB) | 2006-04-19 | — | — | EP | disclosed |
| WO-2005012327-A2 | NUCLEOTIDE PHOSPHORAMIDATES AS ANTICANCER AGENTS | UNIVERSITY COLLEGE CARDIFF CONSULTANTS LIMITED (GB) | 2005-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080105866-A1 | Method of fabricating organic thin film transistor using self assembled monolayer-forming compound containing dichlorophosphoryl group | DIMT1, MTAP, SAMHD1 | CYP1A2 3819/4885CYP2C9 3185/4885CYP2C19 3604/4885 |
| US-20060142238-A1 | Chemical compounds | NUDT1, DCK, PNP | CYP1A2 3861/4885CYP2C9 1589/4885CYP2C19 2835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.